NYSE Amex: CUR received a DOD contract to develop its human neural stem cell technology for the treatment of cancerous brain tumors. Read more…
Allowance for US Patent Applications# 12/939,897 and 12/939,914 entitled: “Compositions to Effect Neuronal Growth Read more…
Q1/11 net loss of $3.1M or $0.07 per share Read more…
CUR has signed a Memorandum of Understanding with BaYi Brain Hospital in Beijing, China. Read more…
Safety results were presented on 9 patients in an ongoing PI study to evaluate the safety of CUR’s spinal cord stem cells (HSSC’s), Read more…
FY10 net loss was $18.38M or $0.42 per share
CUR’s 1st subject was dosed (2/28/11) in a Phase Ia trial to evaluate the safety of its drug, NSI-189, Read more…
Stanley I Westreich is appointed to Board of Directors. Read more…
CUR updated the progress of its ongoing Phase I clinical trial of the spinal cord stem cells in the treatment of ALS Read more…
CUR as reported on Bloomberg received the FDA’s Orphan Drug Designation Read more…
Founder and Director of Research, Henry McCusker enters his tenth (10) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.